Biomarkers of Tobacco Exposure Decrease after Smokers Switch to an E-Cigarette or Nicotine Gum

Nicotine and Tobacco Research

Volumn 21, Issue 9, 2019, Pages 1239-1247

  Round, Elaine K ^a   Chen, Peter ^a   Taylor, Anthony K ^b   Schmidt, Eckhardt ^a  

^a RAI Innovations Company   (United States)

^b ABBVIE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; NICOTINE; NICOTINE GUM;

ADULT; BLOOD; CIGARETTE SMOKING; CONTROLLED STUDY; DANGEROUS GOODS; ELECTRONIC CIGARETTE; FEMALE; HUMAN; MALE; MIDDLE AGED; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SMOKING; SMOKING CESSATION; URINE; VAPING;

ADULT; BIOMARKERS; CIGARETTE SMOKING; ELECTRONIC NICOTINE DELIVERY SYSTEMS; FEMALE; HAZARDOUS SUBSTANCES; HUMANS; MALE; MIDDLE AGED; NICOTINE; NICOTINE CHEWING GUM; SMOKERS; SMOKING CESSATION; VAPING;

EID: 85071551706     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/nty140     Document Type: Article

References (41)

1. U. S. Department of Health and Human Services. How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Washington, DC: Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, U. S. Government Printing Office; 2010.
2. U. S. Department of Health and Human Services. The Health Consequences of Smoking?50 Years of Progress: A Report of the Surgeon General. Washington, DC: Department of Health and Human Services, Public Health Service, Office of the Surgeon General, U. S. Government Printing Office; 2014.
3. Kozlowski LT, Strasser AA, Giovino GA, Erickson PA, Terza JV. Applying the risk/use equilibrium: use medicinal nicotine now for harm reduction. Tob Control. 2001;10(3):201?203.
4. Zeller M, Hatsukami D; Strategic Dialogue on Tobacco Harm Reduction Group. The strategic dialogue on tobacco harm reduction: A vision and blueprint for action in the US. Tob Control. 2009;18(4):324?332.
5. Etter JF. Electronic cigarettes: A survey of users. BMC Public Health. 2010;10:231.
6. Etter JF, Bullen C. Electronic cigarette: users profile, utilization, satisfaction and perceived efficacy. Addiction. 2011;106(11):2017?2028.
7. Etter JF. Characteristics of users and usage of different types of electronic cigarettes: findings from an online survey. Addiction. 2016;111(4):724?733.
8. Piñeiro B, Correa JB, Simmons VN, et al. Gender differences in use and expectancies of e-cigarettes: online survey results. Addict Behav. 2016;52:91?97.
9. Rodu B, Plurphanswat N. E-cigarette use among US adults: population assessment of tobacco and health. Nicotine Tob Res. 2018;20(8):940?948.
10. Royal College of Physicians. Nicotine Without Smoke: Tobacco Harm Reduction. London, UK: RCP; 20https://www.rcplondon.ac.uk/sites/ default/files/media/Documents/Nicotine%20without%20smoke.pdf. Published April 20Accessed November 20, 2017.
11. Goniewicz ML, Knysak J, Gawron M, et al. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tob Control. 2014;23(2):133?139.
12. Kosmider L, Sobczak A, Fik M, et al. Carbonyl compounds in electronic cigarette vapors: effects of nicotine solvent and battery output voltage. Nicotine Tob Res. 2014;16(10):1319?1326.
13. Ohta K, Uchiyama S, Inaba Y, Nakagome H, Kunugita N. Determination of carbonyl compounds generated from the electronic cigarette using coupled silica cartridges impregnated with hydroquinone and 2,4-dinitrophenylhydrazine. Bunseki Kagaku. 2011;60:791?797.
14. Geiss O, Bianchi I, Barahona F, Barrero-Moreno J. Characterisation of mainstream and passive vapours emitted by selected electronic cigarettes. Int J Hyg Environ Health. 2015;218(1):169?180.
15. Blair SL, Epstein SA, Nizkorodov SA, Staimer N. A real-Time fast-flow tube study of VOC and particulate emissions from electronic, potentially reduced-harm, conventional, and reference cigarettes. Aerosol Sci Technol. 2015;49(9):816?827.
16. US Department of Health and Human Services. Premarket Tobacco Product Applications for Electronic Nicotine Delivery Systems, Guidance for Industry, Draft Guidance. Rockville, MD: Food and Drug Administration, Center for Tobacco Products; May 2016.
17. Abrams DB, Niaura R. The importance of science-informed policy and what the data really tell us about e-cigarettes. Isr J Health Policy Res. 2015;4:22.
18. Walton KM, Abrams DB, Bailey WC, et al. NIH electronic cigarette workshop: developing a research agenda. Nicotine Tob Res. 2015;17(2):259?269.
19. Gregg EO, Minet E, McEwan M. Urinary biomarkers of smokers? exposure to tobacco smoke constituents in tobacco products assessment: A fit for purpose approach. Biomarkers. 2013;18(6):467?486.
20. Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer. 2003;3(10):733?744.
21. Hecht SS. Research opportunities related to establishing standards for tobacco products under the Family Smoking Prevention and Tobacco Control Act. Nicotine Tob Res. 2012;14(1):18?28.
22. Hecht SS, Yuan JM, Hatsukami D. Applying tobacco carcinogen and toxicant biomarkers in product regulation and cancer prevention. Chem Res Toxicol. 2010;23(6):1001?1008.
23. Schick SF, Blount BC, Jacob P Rd, et al. Biomarkers of exposure to new and emerging tobacco delivery products. Am J Physiol Lung Cell Mol Physiol. 2017;313(3):L425?L452.
24. Hecht SS, Carmella SG, Kotandeniya D, et al. Evaluation of toxicant and carcinogen metabolites in the urine of e-cigarette users versus cigarette smokers. Nicotine Tob Res. 2015;17(6):704?709.
25. Shahab L, Goniewicz ML, Blount BC, et al. Nicotine, carcinogen, and toxin exposure in long-Term e-cigarette and nicotine replacement therapy users: A cross-sectional study. Ann Intern Med. 2017;166(6):390?400.
26. Kotandeniya D, Carmella SG, Pillsbury ME, Hecht SS. Combined analysis of N?-nitrosonornicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol in the urine of cigarette smokers and e-cigarette users. J Chromatogr B Analyt Technol Biomed Life Sci. 2015;1007:121?126.
27. McRobbie H, Phillips A, Goniewicz ML, et al. Effects of switching to electronic cigarettes with and without concurrent smoking on exposure to nicotine, carbon monoxide, and acrolein. Cancer Prev Res (Phila). 2015;8(9):873?878.
28. Goniewicz ML, Gawron M, Smith DM, Peng M, Jacob P 3rd, Benowitz NL. Exposure to nicotine and selected toxicants in cigarette smokers who switched to electronic cigarettes: A longitudinal within-subjects observational study. Nicotine Tob Res. 2017;19(2):160?167.
29. Cravo AS, Bush J, Sharma G, et al. A randomised, parallel group study to evaluate the safety profile of an electronic vapour product over 12 weeks. Regul Toxicol Pharmacol. 2016;81(suppl 1):S1?S14.
30. D?Ruiz CD, Graff DW, Robinson E. Reductions in biomarkers of exposure, impacts on smoking urge and assessment of product use and tolerability in adult smokers following partial or complete substitution of cigarettes with electronic cigarettes. BMC Public Health. 2016;16:543
31. Wagener TL, Floyd EL, Stepanov I, et al. Have combustible cigarettes met their match? The nicotine delivery profiles and harmful constituent exposures of second-generation and third-generation electronic cigarette users. Tob Control. 2017;26(e1):e23?e28.
32. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: A revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991;86(9):1119?1127.
33. Krautter GR, Borgerding MF. Comparison of consumption patterns, biomarkers of exposure, and subjective effects in cigarette smokers who switched to dissolvable tobacco (Camel Orbs), dual use, or tobacco abstinence. Nicotine Tob Res. 2014;16(10):1336?1347.
34. Theophilus EH, Coggins CR, Chen P, Schmidt E, Borgerding MF. Magnitudes of biomarker reductions in response to controlled reductions in cigarettes smoked per day: A one-week clinical confinement study. Regul Toxicol Pharmacol. 2015;71(2):225?234.
35. Round EK, Campbell LR, Stiles MF, Dixon M, Borgerding MF. Changes in biomarkers of exposure and subjective effects when smokers switch to dual use of cigarettes and either snus or a dissolvable tobacco product ? a summary of three clinical studies. Beiträge zur Tobakforschung/Contrib Tobacco Res. 2015;26(6):242?260.
36. Piller M, Gilch G, Scherer G, Scherer M. Simple, fast and sensitive LC-MS/ MS analysis for the simultaneous quantification of nicotine and 10 of its major metabolites. J Chromatogr B Analyt Technol Biomed Life Sci. 2014;951?952:7?15.
37. US Federal Register. Harmful and potentially harmful constituents in tobacco products and tobacco smoke: established list. 2012;77(64) :20034?200https://www.federalregister.gov/ documents/ 2012/04/03/2012-7727/harmful-And-potentially-harmful-constituents-in-Tobacco-products-And-Tobacco-smokeestablished-list
38. Keeler C, Max W, Yerger V, Yao T, Ong MK, Sung HY. The association of menthol cigarette use with quit attempts, successful cessation, and intention to quit across racial/ethnic groups in the United States. Nicotine Tob Res. 2017;19(12):1450?1464.
39. Krautter GR, Chen PX, Borgerding MF. Consumption patterns and biomarkers of exposure in cigarette smokers switched to Snus, various dissolvable tobacco products, dual use, or tobacco abstinence. Regul Toxicol Pharmacol. 2015;71(2):186?197.
40. Shiffman S, Hughes JR, Di Marino ME, Sweeney CT. Patterns of overthe-counter nicotine gum use: persistent use and concurrent smoking. Addiction. 2003;98(12):1747?1753.
41. Aherrera A, Olmedo P, Grau-Perez M, et al. The association of e-cigarette use with exposure to nickel and chromium: A preliminary study of non-invasive biomarkers. Environ Res. 2017;159:313?320